Myriad Genetics ($MYGN) is headed to Europe to help market a breast cancer test developed by Sividon Diagnostics, a Siemens Healthcare ($SI) spinoff. With the move, Myriad is hoping to add some more diversity to its line of molecular diagnostics. EndoPredict, Sividon's second-generation, multigene prognostic test, has been sold internationally since 2011 and is designed to predict the likelihood of metastasis after more than 5 years. After Myriad's tough patent losses on the BRCA1 and BRCA2 fronts last summer, the company is hoping to cash in on the "high growth" European market, which includes more than 388,000 women annually suffering from breast cancer, Sividon CEO Christoph Petry notes. Myriad's growing presence overseas reflects its efforts to stand apart from an ever-crowded space. More from FierceDiagnostics